(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Addressing sleep apnea early might decrease chances of developing Parkinson's disease - 2Dominating Capable Mastercard Utilization: Key Contemplations
- 3Blue Origin safely launches wheelchair user to space and back
- 4Father and son spending Christmas together after health scares
- 5Manual for Big name Work out schedules
- Pick Your Number one breakfast food
- Pick Your Number one sort of blossom
- ‘And then we saw the little head.’ Scientists witness rare sperm whale birth
- Manual for extravagance SUVs for seniors
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- Dirty soda started as a Mormon alternative to booze. Now it's everywhere.
- Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- US measles cases surpass 2,000, highest in 30 years: CDC
- Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget
